The Clinical Study Report (CSR) is the comprehensive final report of a clinical trial. It summarises the study design, conduct, methodology, statistical analyses and results in a way that enables authorities, ethics committees and internal stakeholders to understand and assess the study. In marketing authorisation projects, the CSR is a key document that typically feeds into the electronic Common Technical Document (eCTD). Without a high-quality CSR, regulatory submissions—especially for pivotal registration studies—are incomplete and do not meet the expectations of the EMA or national authorities.
Purpose and areas of application of a CSR
A CSR documents not only “what the outcome was”, but also how the results were generated: Which population was enrolled, how were endpoints measured, which protocol deviations occurred, and how were the data analysed statistically? The CSR therefore provides a basis for regulatory decisions, benefit–risk assessments and—where required—inspections or audits in accordance with GCP standards (ICH E6(R3)).
CSRs are prepared in particular for pivotal studies (e.g., Phase III), but may also be relevant for Phase I/II, for example in early development programmes, orphan drug strategies, or in the context of Scientific Advice. In the context of the EU Regulation CTR 536/2014, sponsors are also required to publish study results via the Clinical Trials Information System (CTIS)—the CSR is often the substantive basis for this.
In addition, the CSR serves as a reference document for the Medical Writing team when preparing publications, regulatory summaries and plain-language result summaries (lay summaries), which are mandatory under CTR 536/2014.
Regulatory framework: ICH E3 and current requirements
The classic structure of a CSR is based on the ICH E3 guideline “Structure and Content of Clinical Study Reports”. This guideline defines the content, structure and level of detail of the report and is accepted by authorities worldwide. In Europe, additional requirements apply from Good Clinical Practice (ICH E6(R3)) and—depending on the context—requirements from CTR 536/2014, particularly with regard to submission and transparency processes via CTIS.
Regulatory Affairs and Medical Writing work closely together to ensure consistency between the CSR, protocol, statistical analysis plan (SAP) and submission dossier. Inconsistencies between these documents—such as differing patient numbers or differently defined analysis populations—are a frequent trigger for authority queries (Day 80/120 Questions in the centralised EU procedure) and can significantly delay marketing authorisation processes.
Typical content and structure
A CSR is extensive and follows a standardised logic. Typical components include:
- Synopsis: Concise summary of the key study parameters, methods and results.
- Study rationale & objectives: Background, hypotheses, primary and secondary endpoints.
- Methods: Study design, randomisation and blinding, inclusion criteria, investigational medicinal product, statistical methods and sample size planning.
- Results: Patient flow (CONSORT diagram), demographics and baseline, efficacy results, safety data including adverse events (AEs/SAEs), subgroup analyses.
- Protocol deviations & data integrity: Relevant deviations, data quality, monitoring aspects and GCP compliance.
- Discussion & conclusions: Interpretation in the clinical and regulatory context, limitations and conclusions for further development.
- Appendices: Protocol and amendments, Investigator’s Brochure references, complete tables, listings and figures (TLFs), AE listings.
Data basis, statistics and inspection readiness
A CSR is only as robust as the underlying data. Therefore, alignment with clinical data management (EDC/CRF systems), biostatistics (SAP, outputs) and clinical monitoring is critical. Key milestones that often need to be completed before CSR preparation include database lock and finalisation of the analysis populations—typically intention-to-treat (ITT) and per-protocol (PP).
The interaction between the sponsor, the CRO and external biostatisticians is particularly critical: changes to the SAP after database lock are regulatorily sensitive and must be well justified and documented. Data integrity issues—such as non-traceable data re-entry or missing source data verification—can call the entire CSR into question and lead to critical findings in GCP inspections.
Modern data management systems such as central electronic data capture (EDC) with integrated risk-based monitoring concepts in accordance with ICH E6(R3) help to ensure data quality during the study and accelerate the CSR development process.
Authorities also expect a CSR to be consistent, complete and auditable. This includes, among other things: clear version control with date and author accountability, traceable justifications for deviations, consistent figures across synopsis, narrative text and tables, and clear traceability to the protocol, SAP and raw data.
In GCP inspections by the EMA or national authorities (e.g., BfArM, ANSM, MHRA), it is also assessed whether report preparation was conducted within the framework of SOPs and quality processes. A frequent point of criticism is insufficient documentation of the review process: who reviewed and approved which version, and when? Quality management systems and clearly defined review cycles—including statistical, medical and regulatory review—are therefore indispensable.
The completeness of the appendices is also reviewed during inspections. Missing or incomplete listings of adverse events, protocol deviations or investigator documentation are typical findings that must be remediated and can jeopardise timelines.
Frequently Asked Questions (FAQ)
When does preparation of a Clinical Study Report begin?
The actual drafting often starts after database lock, once the final statistical outputs are available. However, planning, the CSR outline and templates can be prepared earlier to safeguard timelines. Experienced medical writers also often begin drafting the methods and background sections in parallel with ongoing data capture.
How does a CSR differ from a publication?
A scientific publication is highly condensed, aimed at the specialist community and subject to the requirements of the respective journal. A CSR is far more extensive, follows regulatory requirements (ICH E3) and includes all raw data references, listings and appendices necessary for regulatory review. Publications and the CSR must not be inconsistent in content.
Which teams are typically involved in the CSR?
Typically, Medical Writing, Biostatistics, Clinical Data Management, Clinical Project Management, Pharmacovigilance/Safety and Regulatory Affairs—depending on the sponsor set-up, also CRO teams. In addition, Quality Assurance and often the study lead (Principal Investigator or the sponsor’s medically/scientifically responsible person) are involved in the final review.
Regulatory References
- ICH E3: Structure and Content of Clinical Study Reports
- ICH E6(R3) Guideline for Good Clinical Practice
- EU Clinical Trials Regulation (CTR) 536/2014
- EMA Guideline on the content, management and archiving of the clinical trial master file (CTF)
- EMA Reflection Paper on Risk-Based Quality Management in Clinical Trials